Question · asked by 1 review
Intestinal trefoil factor (ITF), lower dose (336 mg) vs Intestinal trefoil factor (ITF), higher dose (2688 mg): Oral mucositis (any severity)
- Population
- Adults receiving chemotherapy alone for colorectal cancer
- Intervention
- Intestinal trefoil factor (ITF), lower dose (336 mg)
- Comparison
- Intestinal trefoil factor (ITF), higher dose (2688 mg)
- Outcome
- Oral mucositis (any severity)
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Intestinal trefoil factor (ITF), lower dose (336 mg) vs Intestinal trefoil factor (ITF), higher dose (2688 mg) Oral mucositis (any severity) · Adults receiving chemotherapy alone for colorectal cancer Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and… (2017) · Cochrane All outcomes | Insufficient evidence to determine whether lower (336 mg) or higher (2688 mg) dose performs better (Analyses 11.1 to 11.3); no pooled estimate reported | 1 study · 66 participants | GRADE not reported |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes | 2017-05 | Not listed | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.